KR950031065A - 지방산 유도체 - Google Patents

지방산 유도체 Download PDF

Info

Publication number
KR950031065A
KR950031065A KR1019950004287A KR19950004287A KR950031065A KR 950031065 A KR950031065 A KR 950031065A KR 1019950004287 A KR1019950004287 A KR 1019950004287A KR 19950004287 A KR19950004287 A KR 19950004287A KR 950031065 A KR950031065 A KR 950031065A
Authority
KR
South Korea
Prior art keywords
ascorbyl
dgla
gla
weight
prescribed
Prior art date
Application number
KR1019950004287A
Other languages
English (en)
Inventor
프레데릭 호로빈 데이비드
노울스 필립
싱흐 만쿠 메하르
Original Assignee
카트리오나 프랑세스 마르
스코티아 홀딩스 피엘씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카트리오나 프랑세스 마르, 스코티아 홀딩스 피엘씨. filed Critical 카트리오나 프랑세스 마르
Publication of KR950031065A publication Critical patent/KR950031065A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Fats And Perfumes (AREA)
  • Furan Compounds (AREA)

Abstract

본 발명은 천식 및 이에 관련된 질병의 치료를 위한 약물에 사용되어지는 아스코르빌-GLA나 아스코르빌-DGLA에 관한 것이다.

Description

지방산 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기는 질병 : (a) 천식 및 이에 관련된 질병 (b) 아테름성 동맥경화증 또는 증가된 콜레스테롤 치 또는 고혈압증 또는 혈소판 응집 과도증과 관련된 심장 혈관계 질병 (c) 유(類)류머티스 관절염, 골관절염 및 그외의 염증질환 (d) 암의 치료를 위한 약물의 제조나 약물 요법에 사용되어짐을 특징으로 하는 아스코르빌-GLA나 아스코르빌-DGLA의 용도.
  2. 제1항에 있어서, 일일 0.1㎎∼50g, 바람직하게는 일일 10㎎∼10g, 더욱 바람직하게는 일일 100㎎∼5g으로 투여량으로 처방되어짐을 특징으로 하는 아스코르빌-GLA나 아스코르빌-DGLA의 용도.
  3. 제1항, 제2항 또는 제3항에 있어서, 조성물의 전체 중량에 대해 0.001∼50중량%, 바람직하게는 0.1∼20중량%, 더욱 바람직하게는 1∼10중량%으로 처방되어짐을 특징으로 하는 아스코르빌-GLA나 아스코르빌-DGLA의 용도.
  4. 제1항, 제2항 또는 제3항에 있어서, 천식 및 이에 관련된 질병에 대하여 호흡기로 화합물의 수송을 위한 현탄액, 분무제, 에어로졸, 리포좀이나 그밖의 다른 형태로 처방되어짐을 특징으로 하는 아스코르빌-GLA나 아스코르빌-DGLA의 용도.
  5. 제1항, 제2항 또는 제3항에 있어서, 유리 지방산이나 트리글리세리드에 용해된 형태의 GLA, DGLA 또는 EPA를 5중량% 이상 함유하는 오일(oil)과 혼합하여 처방되어짐을 특징으로 하는 아스코르빌-GLA나 아스코르빌-DGLA의 용도.
  6. 치료 요법이나 화장품, 피부 보호제 혹은 영양 보충식을 함유하는 모든 형태의 음식에 사용되어짐을 특징으로 하는 아스코르빌-DGLA.
  7. 치료 요법이나 영양 보충식을 함유하는 모든 형태의 음식에 사용됨을 특징으로 하는 아스코르빌-GLA.
  8. 호흡기로의 화합물의 수송을 위한 분무제, 현탄액, 에어로졸, 리포좀이나 그밖의 다른 형태로 처방되어짐을 특징으로 하는 아스코르빌-GLA나 아스코르빌-DGLA.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950004287A 1994-03-01 1995-03-02 지방산 유도체 KR950031065A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9403855A GB9403855D0 (en) 1994-03-01 1994-03-01 Fatty acid derivatives
GB9403855,1 1994-03-01

Publications (1)

Publication Number Publication Date
KR950031065A true KR950031065A (ko) 1995-12-18

Family

ID=10751060

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950004287A KR950031065A (ko) 1994-03-01 1995-03-02 지방산 유도체

Country Status (19)

Country Link
US (2) US5847000A (ko)
EP (1) EP0675120B1 (ko)
JP (1) JPH07309753A (ko)
KR (1) KR950031065A (ko)
CN (1) CN1111508A (ko)
AT (1) ATE208384T1 (ko)
AU (1) AU703651B2 (ko)
CA (1) CA2143603A1 (ko)
DE (1) DE69523654T2 (ko)
DK (1) DK0675120T3 (ko)
ES (1) ES2167401T3 (ko)
FI (1) FI950909A (ko)
GB (1) GB9403855D0 (ko)
NO (1) NO950784L (ko)
NZ (1) NZ270575A (ko)
PT (1) PT675120E (ko)
SG (1) SG50339A1 (ko)
TW (1) TW360537B (ko)
ZA (1) ZA951505B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138431B1 (en) * 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
EE200300599A (et) * 2001-05-30 2004-02-16 Laxdale Limited Koensüüm Q ja EPA või muu asendamatu rasvhape
JP3847693B2 (ja) * 2002-09-30 2006-11-22 シャープ株式会社 半導体装置の製造方法
CN1816287A (zh) * 2003-01-31 2006-08-09 宝洁公司 改善哺乳动物角质组织外观的方法
US20050123500A1 (en) * 2003-01-31 2005-06-09 The Procter & Gamble Company Means for improving the appearance of mammalian hair and nails
CN1805948A (zh) * 2003-04-21 2006-07-19 塔格拉生物科技有限公司 抗坏血酸的稳定衍生物
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
JP2006056795A (ja) * 2004-08-18 2006-03-02 Suntory Ltd ６−ｏ−ｐｕｆａアスコルビン酸エステルを含有する皮膚化粧料並びに飲食品
GB0907413D0 (en) * 2009-04-29 2009-06-10 Equateq Ltd Novel methods
MX2013007191A (es) * 2010-12-21 2013-07-12 Nestec Sa Metodos y composiciones para prevenir y tratar la osteoartritis.
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
EP2708230A4 (en) * 2011-05-12 2014-12-03 Nippon Suisan Kaisha Ltd COMPOSITION FOR APPEARANCE ON THE SKIN FOR INFLAMMATORY DISEASES
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
CA2932728C (en) 2013-12-04 2023-10-10 Nippon Suisan Kaisha, Ltd. Microbial oil, production method for microbial oil, concentrated microbial oil, and production method for concentrated microbial oil
JP5792330B2 (ja) * 2014-01-27 2015-10-07 サントリーホールディングス株式会社 ６−ｏ−ｐｕｆａアスコルビン酸エステルを含有する皮膚化粧料並びに飲食品
US9682055B2 (en) * 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
US10639313B2 (en) 2017-09-01 2020-05-05 Ndsu Research Foundation Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE639776C (de) * 1934-06-12 1936-12-12 Hoffmanni La Roche & Co Akt Ge Verfahren zur Darstellung von Verbindungen der Ascorbinsaeure
CH339632A (de) * 1955-07-07 1959-07-15 Uni Chemie Ag Verfahren zur Darstellung von Verbindungen mit Vitamin-C- und -F-Wirkung
BE639828A (ko) * 1962-11-14
DE1231848B (de) * 1965-04-15 1967-01-05 Thomae Gmbh Dr K Verfahren zur Herstellung von stabilen Vitamin-C-haltigen Tabletten
CH631451A5 (de) * 1976-10-05 1982-08-13 Univ Kansas State Verfahren zur herstellung von fettsaeureester der ascorbinsaeure.
GB1580444A (en) * 1976-11-04 1980-12-03 Bio Oil Res Pharmaceutical compositions
US4289702A (en) * 1977-12-16 1981-09-15 Pfizer Inc. Preparation of erythorbic acid and ascorbis acid 6-fatty acid esters
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
IE53332B1 (en) * 1980-03-14 1988-10-26 Efamol Ltd Pharmaceutical compositions
DE3366838D1 (en) * 1982-03-01 1986-11-20 Efamol Ltd Pharmaceutical composition
AU1933383A (en) * 1982-09-22 1984-03-29 Sentrachem Limited Composition of prostaglandins for prevention of cancer
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
DE3308922A1 (de) * 1983-03-12 1984-09-13 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von fettsaeureestern der ascorbinsaeure
JPS59199636A (ja) * 1983-04-26 1984-11-12 Nippon Mejifuijitsukusu Kk 放射性診断剤
ATE82684T1 (de) * 1984-03-07 1992-12-15 Roshdy Ismail Mittel zur behandlung und zum schutz der haut.
US4818521A (en) * 1985-04-18 1989-04-04 Sunstar Kabushiki Kaisha Emulsion cosmetic stably containing vitamin C
US4792418A (en) * 1985-08-14 1988-12-20 Century Laboratories, Inc. Method of extraction and purification of polyunsaturated fatty acids from natural sources
US4822898A (en) * 1985-09-20 1989-04-18 Sumitomo Chemical Company, Limited Ascorbic acid or erythorbic acid derivatives
JPS6281307A (ja) * 1985-10-04 1987-04-14 Kanebo Ltd 皮膚化粧料
JP2869650B2 (ja) * 1987-05-15 1999-03-10 チッソ株式会社 光学活性化合物およびその製造方法
DK291588A (da) * 1987-06-26 1988-12-27 Hoffmann La Roche Fremgangsmaade til fremstilling af ascorbinsyre-6-estere
JPH0818963B2 (ja) * 1987-09-28 1996-02-28 サンスター株式会社 美白化粧料
DE3820693A1 (de) * 1988-06-18 1989-12-21 Henkel Kgaa Topische kosmetische und pharmazeutische zubereitungen
US5591446A (en) * 1989-04-04 1997-01-07 Beiersdorf, A.G. Methods and agents for the prophylaxis of atopy
EP0398484B1 (en) * 1989-05-19 1995-05-31 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Alpha-glycosyl-L-ascorbic acid, and its preparation and uses
DE69016838T2 (de) * 1989-06-03 1995-07-20 Mitsubishi Rayon Co Verfahren zur Herstellung von organischen Estern.
JP2831395B2 (ja) * 1989-09-12 1998-12-02 ハリマ化成株式会社 アスコルビン酸エステル
US5574063A (en) * 1989-10-12 1996-11-12 Perricone; Nicholas V. Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage
US5122536A (en) * 1989-10-12 1992-06-16 Perricone Nicholas V Method for the topical treatment of psoriasis
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
US5078989A (en) * 1990-03-28 1992-01-07 Sunstar K.K. Skin whitening cosmetics
JPH05209968A (ja) * 1990-12-28 1993-08-20 Hamamatsu Photonics Kk 放射線検出装置
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
DE4133694C2 (de) * 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JPH05219970A (ja) * 1992-02-10 1993-08-31 Mitsubishi Rayon Co Ltd 有機酸エステルの製造法
GB9213322D0 (en) * 1992-06-23 1992-08-05 Efamol Holdings Antioxidant compositions
GB9217780D0 (en) * 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases
US5516793A (en) * 1993-04-26 1996-05-14 Avon Products, Inc. Use of ascorbic acid to reduce irritation of topically applied active ingredients
AU691250B2 (en) * 1994-02-04 1998-05-14 Lipocore Holding Ab Lipophilic carrier preparations
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications

Also Published As

Publication number Publication date
CN1111508A (zh) 1995-11-15
US6177470B1 (en) 2001-01-23
ES2167401T3 (es) 2002-05-16
AU1340895A (en) 1995-09-07
NO950784D0 (no) 1995-02-28
DK0675120T3 (da) 2002-03-11
GB9403855D0 (en) 1994-04-20
DE69523654D1 (de) 2001-12-13
ZA951505B (en) 1995-12-08
EP0675120A3 (en) 1998-07-08
FI950909A (fi) 1995-09-02
EP0675120B1 (en) 2001-11-07
PT675120E (pt) 2002-04-29
NO950784L (no) 1995-09-04
AU703651B2 (en) 1999-04-01
CA2143603A1 (en) 1995-09-02
TW360537B (en) 1999-06-11
NZ270575A (en) 1998-08-26
EP0675120A2 (en) 1995-10-04
JPH07309753A (ja) 1995-11-28
US5847000A (en) 1998-12-08
ATE208384T1 (de) 2001-11-15
FI950909A0 (fi) 1995-02-28
SG50339A1 (en) 1998-07-20
DE69523654T2 (de) 2002-08-01

Similar Documents

Publication Publication Date Title
KR950031065A (ko) 지방산 유도체
PT787489E (pt) Composicao contendo propionil-l-carnitina e acido hidroxicitrico ou acido pantotenico
HUP0100430A2 (hu) Strukturált glicerideket tartalmazó készítmény, valamint alkalmazása zsíroldékony vegyületek felszívódásának fokozására
NZ319090A (en) (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
CA2180571A1 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
MX9303799A (es) Derivados de la serie de vitamina d con modificaciones en la posicon 20, procedimiento para su preparacion, productos intermedios para este procedimiento, preparados farmaceuticos que contienen estos derivados asi como su utilizacion para la prod.
EP0226223A3 (en) Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity
BR0014154A (pt) Esterol aciltransferases vegetais
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
ATE115585T1 (de) Bilobalid-phospholipid-komplexe, ihre anwendung und zusammensetzungen enthaltend diese.
MX9708416A (es) Derivados de piperazino como antagonistas de neuroquininas.
ATE149033T1 (de) Pyridazindionderivate, ihre herstellung und verwendung als arzneimittel
ES8707111A1 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
IT8748404A0 (it) O-alcanoil derivati dell'acido 3ammino-2-idrossipropansolfonico adattivita'anticonvulsivante e loro composizioni farmaceutiche per il trattamento terapeutico dell'epilessia
IT1260155B (it) Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
ATE15331T1 (de) Verfahren fuer die orale verabreichung von substanzen in der form von liposomen, und ihre pharmazeutischen zusammensetzungen.
IT1232352B (it) Derivati dell'acido chinurenico ad attivita' sul sistema nervoso centrale, loro preparazione e relative composizioni farmaceutiche
IT1227158B (it) Esteri dell'acido tiamorfolinone carbossilico e di suoi derivati, loro procedimento di preparazione e loro impiego nel settore cosmetico e nel settore dermo farmaceutico.
IT8747964A0 (it) N-ftaloil derivati dell'acido 3-amminopropansolfonico ad attivita'anticonvulsivante e loro composizioni farmaceutiche per il trattamento terapeutico dell'epilessia
IT8747895A0 (it) N-cinnamoil derivati dell'acido 3 amminopropansolfonico ad attivita'anticonvulsivante e loro composizioni farmaceutiche per il trattamento terapeutico dell'epilessia

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application